MoneyWorks4Me

Ajanta Pharma informs about newspaper publication

31 Aug 2026 Evaluate

Pursuant to Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Ajanta Pharma has informed that it enclosed copy of notice published in Free Press Journal (English) & Navshakti (Marathi) newspapers on Friday, 28th August 2026, inviting attention of concerned shareholders to lodge their claims in respect of unclaimed dividends of the Company for last seven years, failing which their underlying shares will be transferred to the Investor Education and Protection Fund (‘IEPF’) account, in accordance with section 124(6) of the Companies Act, 2013 read with Rules

The above information is a part of company’s filings submitted to BSE.


Ajanta Pharma Share Price

3481.35 -39.90 (-1.13%)
04-Sep-2026 14:16 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1899.10
Dr. Reddys Labs. 1158.00
Cipla 1380.55
Lupin 2110.00
Zydus Lifesciences 1129.10
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: